G&A

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

Retrieved on: 
Mardi, mai 7, 2024
The Adecco Group, G&A, FESCO, Element, LHH, Aquaculture

We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business.

Key Points: 
  • We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business.
  • Akkodis faced ongoing tech staffing headwinds while achieving solid growth in its higher-value consulting business, which lifted overall profitability.
  • In LHH, Career Transition and Ezra once again outperformed, and the business delivered an improved margin.
  • We remain laser-focused on the elements within our control – competitive outperformance and market share expansion, together with cost discipline.

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

Retrieved on: 
Mardi, mai 7, 2024
The Adecco Group, G&A, FESCO, Element, LHH, Aquaculture

We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business.

Key Points: 
  • We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business.
  • Akkodis faced ongoing tech staffing headwinds while achieving solid growth in its higher-value consulting business, which lifted overall profitability.
  • In LHH, Career Transition and Ezra once again outperformed, and the business delivered an improved margin.
  • We remain laser-focused on the elements within our control – competitive outperformance and market share expansion, together with cost discipline.

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Vendredi, mai 3, 2024
FDA, Food, BDII, GHRS, Research, Psychiatry, New Drug Application, Insurance, TRD, Psychotherapy, IND, Patient, DSM-IV codes, Clinical trial, PD, G&A, Rat, Pharmaceutical industry

DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.
  • We continue to expect GH001-PPD-203 completion and availability of top-line data in the third quarter of 2024.
  • R&D expenses were $8.7 million for the quarter ended March 31, 2024, compared to $7.3 million for same quarter in 2023.
  • G&A expenses were $2.9 million for the quarter ended March 31, 2024, compared to $3.1 million for the same quarter in 2023.

Coterra Energy Reports First-Quarter 2024 Results, Announces Quarterly Dividend, and Updates 2024 Outlook

Retrieved on: 
Jeudi, mai 2, 2024
Oil, Gas, Energy, Table, Common, Investment, Atlas, Natural gas, Electricity, Transport, Webcast, NYMEX, Free cash flow, Public expenditure, LNG, WTI, Share repurchase, GAAP, G&A, Bank

Coterra Energy Inc. (NYSE: CTRA) (“Coterra” or the “Company”) today reported first-quarter 2024 financial and operating results and declared a quarterly dividend of $0.21 per share.

Key Points: 
  • Coterra Energy Inc. (NYSE: CTRA) (“Coterra” or the “Company”) today reported first-quarter 2024 financial and operating results and declared a quarterly dividend of $0.21 per share.
  • For more details on annual and second quarter 2024 guidance, see 2024 Guidance Section in the tables below.
  • As of March 31, 2024, Coterra had total debt outstanding of $2.651 billion, of which $575 million is due in September 2024.
  • Coterra will host a conference call tomorrow, Friday, May 3, 2024, at 8:00 AM CT (9:00 AM ET), to discuss first-quarter 2024 financial and operating results.

CENTURY LITHIUM ANNOUNCES POSITIVE FEASIBILITY STUDY FOR THE CLAYTON VALLEY LITHIUM PROJECT, NEVADA

Retrieved on: 
Lundi, avril 29, 2024
Lithium, Benchmark Mineral Intelligence, Project, Sale, DLE, Filtration, H2SO4, Risk, Pilot plant, Sodium chloride, GRE, Project management, Mineral, Area studies, Lithium carbonate, Transport, QP, Mineral Resources Limited, AACE, FOB, Hydrochloric acid, Patent, MMSA, Feasibility study, Sodium hydroxide, Commerce, Hydrogen chloride, Century, Mining, CIM, Electrolysis, Recycling, G&A, Saltern

The QP for the estimate is Ms. Terre Lane, MMSA, an employee of GRE and independent of Century.

Key Points: 
  • The QP for the estimate is Ms. Terre Lane, MMSA, an employee of GRE and independent of Century.
  • Metallurgical testing through 2020 focused on using sulfuric acid (H2SO4) to extract lithium from the clay.
  • A lithium recovery of 78% is used in the Feasibility Study, based on the data collected in over two years of operations at the Pilot Pant.
  • Contributors to the estimates are GRE (mining), Wood (process plant and infrastructure), ThyssenKrupp Nucera (chlor-alkali plant) and Century Lithium (property information and owners' costs).

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Jeudi, mai 2, 2024
Sale, American Academy, Episcopal conference, MDA, Research, Muscular Dystrophy Association, DMD, Conference, Therapy, DYN, DM1, G&A, Pharmaceutical industry

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.
  • Research and development (R&D) expenses: R&D expenses were $44.5 million for the quarter ended March 31, 2024, compared to $37.5 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $24.6 million for the quarter ended March 31, 2024, compared to $7.9 million for the quarter ended March 31, 2023.
  • Net loss: Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.

El Pollo Loco Holdings, Inc. Announces First Quarter 2024 Financial Results

Retrieved on: 
Jeudi, mai 2, 2024
Sale, Net income, Meal, Share repurchase, Depreciation, Holiday, Key, Insurance, Webcast, Growth, Restaurant, Public expenditure, IPO, Revolver, Comparable, Income tax, Digital first, Food, Vii, Loss, Adjustment, Drink, Overalls, GAAP, G&A, El Pollo Loco

COSTA MESA, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended March 27, 2024.

Key Points: 
  • COSTA MESA, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended March 27, 2024.
  • A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure is included in the accompanying financial data.
  • Liz Williams, Chief Executive Officer of El Pollo Loco Holdings, Inc., stated, “The strength of the El Pollo Loco brand centers around our signature product – fire-grilled, citrus-marinated chicken that is prepared fresh daily for our customers.
  • The Company will host a conference call to discuss financial results for the first quarter of 2024 today at 4:30 PM Eastern Time.

Galapagos reports first quarter 2024 financial results  

Retrieved on: 
Jeudi, mai 2, 2024
Sale, Element, Burn, Economics, Lupus, Investigational New Drug, Acquisition, Loss, S&M, G&A, TYK2, Pharmaceutical industry

Product net sales of Jyseleca® in Europe were €11.3 million for the first three months of 2024 consisting of sales to customers in January 2024.

Key Points: 
  • Product net sales of Jyseleca® in Europe were €11.3 million for the first three months of 2024 consisting of sales to customers in January 2024.
  • As from 1 February 2024, all economics linked to the sales of Jyseleca® in Europe are to the benefit of Alfasigma.
  • Cost of sales related to Jyseleca® net sales were €1.9 million for the first three months of 2024.
  • Cash, cash equivalents and current financial investments totaled €3,557.9 million as of 31 March 2024, as compared to €3,684.5 million as of 31 December 2023.

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, avril 25, 2024
University, Separable space, General counsel, Atlas, Research, Plan, Employment, ARCA, Internal Revenue Code, Senior, Consultant, Acquisition, Accounting, Medicine, Committee, G&A, Pharmaceutical industry

WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.

Key Points: 
  • WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.
  • In April 2022, ARCA established a Special Committee of the board of directors (the “Board”) of ARCA to conduct a comprehensive review of strategic alternatives.
  • In connection with Dr. Bristow’s separation, ARCA and Dr. Bristow entered into a separation agreement (the “Separation Agreement”) on April 3, 2024.
  • Total operating expenses for the quarter ended March 31, 2024 were $2.5 million compared to $1.8 million for the first quarter 2023.

OMNI-LITE INDUSTRIES REPORTS FOURTH QUARTER AND FISCAL 2023 RESULTS AND CONFERENCE CALL FOR INVESTORS: APRIL 19, 2024, AT 11:00 AM EDT

Retrieved on: 
Jeudi, avril 18, 2024
Sale, Fiscal, EDT, Depreciation, Financial statement, Public expenditure, Tax, OML, Analysis, Acquisition, LOS, G&A, Growth

LOS ANGELES, CALIFORNIA, April 18, 2024 (GLOBE NEWSWIRE) -- Omni-Lite Industries Canada Inc. (the "Company" or “Omni-Lite”; TSXV: OML) today reported results for the fourth quarter and fiscal year ending December 31, 2023. Full financial results are available at sedar.com.

Key Points: 
  • Revenue for the fourth quarter of fiscal 2023 was approximately US$3.3 million, an increase of 6% as compared to the fourth quarter of fiscal 2022.
  • Adjusted EBITDA (1) was approximately US$78,000 as compared to approximately US$(270,000) in the fourth quarter of fiscal 2022.
  • Net income for the quarter was US$477,000, or US$0.03 per diluted share, which was impacted by two non-recurring items.
  • Bookings in the fourth quarter of 2023 were approximately US$4.3 million, up 48% as compared to the fourth quarter of fiscal 2022.